文献速递认知障碍与痴呆

认知正常老年人嗅觉障碍与神经影像生物标志物的关联

Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals.
PubMed 文献 · Ann Neurol · 2017-06-09

在Mayo Clinic老化研究队列中,829名认知正常老年人接受嗅觉识别测试和神经影像检查。结果显示,AD特征性皮质厚度异常、海马体积减小和淀粉样蛋白沉积增加与嗅觉识别能力下降及嗅觉缺失风险升高相关。嗅觉测试可能作为无创、廉价的阿尔茨海默病临床前阶段风险分层工具。

要点

  • AD特征性皮质厚度异常和海马体积减小与嗅觉识别能力下降相关
  • 海马体积减小、皮质厚度异常和淀粉样蛋白沉积增加与嗅觉缺失风险升高相关
  • 嗅觉识别测试或可用于识别AD临床前阶段的高风险个体

核心结论

  • 嗅觉识别能力下降与AD相关神经影像生物标志物异常相关,可能作为识别AD临床前阶段个体的无创、廉价标志物。

研究设计与样本

  • 基于人群的Mayo Clinic老化研究横断面分析,纳入829名认知正常老年人(平均年龄79.2岁,51.5%男性)。
  • 嗅觉功能采用简要气味识别测试(B-SIT)评估,神经影像包括MRI(n=829)评估AD特征性皮质厚度复合指标和海马体积,11C-PiB PET(n=306)评估淀粉样蛋白沉积,18F-FDG PET(n=305)评估脑低代谢。
  • 采用多项逻辑回归和简单线性回归模型分析神经影像生物标志物与嗅觉识别的关联,并校正潜在混杂因素。

主要发现

  • 829名认知正常参与者中,248人(29.9%)嗅觉正常,78人(9.4%)嗅觉缺失(B-SIT评分<6)。
  • AD特征性皮质厚度异常与嗅觉识别能力连续测量值下降相关(斜率=-0.43,95%CI -0.76至-0.09,p=0.01)。
  • 海马体积减小与嗅觉识别能力连续测量值下降相关(斜率=-0.72,95%CI -1.15至-0.28,p<0.01)。
  • 海马体积减小、AD特征性皮质厚度异常和淀粉样蛋白沉积增加均与嗅觉缺失风险升高显著相关。

临床怎么用

  • 在认知正常老年人中,嗅觉识别测试可作为无创、廉价的工具,辅助识别AD临床前阶段高风险个体,用于预防试验筛选。
  • 嗅觉识别能力下降应提示进一步评估AD相关神经影像生物标志物,但需结合临床综合判断。

局限性

  • 横断面设计,无法确定因果关系, findings 尚需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is a need for inexpensive noninvasive tests to identify older healthy persons at risk for Alzheimer disease (AD) for enrollment in AD prevention trials. Our objective was to examine whether abnormalities in neuroimaging measures of amyloid and neurodegeneration are correlated with odor identification (OI) in the population-based Mayo Clinic Study of Aging. METHODS: Cognitively normal (CN) participants had olfactory function assessed using the Brief Smell Identification Test (B-SIT), underwent magnetic resonance imaging (n = 829) to assess a composite AD signature cortical thickness and hippocampal volume (HVa), and underwent 11 C-Pittsburgh compound B (n = 306) and 18 fluorodeoxyglucose (n = 305) positron emission tomography scanning to assess amyloid accumulation and brain hypometabolism, respectively. The association of neuroimaging biomarkers with OI was examined using multinomial logistic regression and simple linear regression models adjusted for potential confounders. RESULTS: Among 829 CN participants (mean age = 79.2 years; 51.5% men), 248 (29.9%) were normosmic and 78 (9.4%) had anosmia (B-SIT score < 6). Abnormal AD signature cortical thickness and reduced HVa were associated with decreased OI as a continuous measure (slope = -0.43, 95% confidence interval [CI] = -0.76 to -0.09, p = 0.01 and slope = -0.72, 95% CI = -1.15 to -0.28, p < 0.01, respectively). Reduced HVa, decreased AD signature cortical thickness, and increased amyloid accumulation were significantly associated with increased odds of anosmia. INTERPRETATION: Our findings suggest that OI may be a noninvasive, inexpensive marker for risk stratification, for identifying participants at the preclinical stage of AD who may be at risk for cognitive impairment and eligible for inclusion in AD prevention clinical trials. These cross-sectional findings remain to be validated prospectively. Ann Neurol 2017;81:871-882.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Vassilaki M, Christianson TJ, Mielke MM, et al. Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals. Ann Neurol. 2017. PMID: 28543731. doi:10.1002/ana.24960

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。